Merck & Co., Inc. Buys Hanwha Drug-Marketing Rights for $720 Million

South Korea's Hanwha Chemical said on Monday it had won a license deal worth $720 million for its biosimilar product with Merck Sharp & Dohme Research Ltd, a subsidiary of U.S. drug firm Merck & Co.